United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies. CIBINQO will be available in Japan in doses of 100mg and 200mg. “There have been limited treatment options available

Japan's MHLW Approves Pfizer's CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Pfizer's getting closer to vaccinating a younger population.

This One Factor Will Determine if Pfizer Can Dominate the Kids' Vaccine Market

The big drugmaker has some major challenges on the way.

Here's a Chart That Every Pfizer Investor Needs to See

AstraZeneca

Major biotech and pharmaceutical companies such as AstraZeneca PLC (NASDAQ: AZN) and Pfizer Inc. (NYSE: PFE) have been some of the best investments to make throughout the COVID-19 pandemic.  Let's take a look at some of the major players in the biotech industry and see how they are moving today:

Why AstraZeneca And Pfizer Shares Are Moving Today

Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.

Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA

Amplify Travel Tech ETF

US Global Jets ETF

Financial Select Sector SPDR Fund

iShares Core S&P Small Cap ETF

We discuss some of the hot events of the first nine months of this year that influenced the market in a big way.

5 Top ETF Stories of Nine Months of 2021

"I wouldn't foreclose the possibility that this could be out in October," the former FDA commissioner said.

Pfizer board member Gottlieb says Covid vaccine approval for young kids by Halloween is still possible

Pfizer said a trial of its new pneumococcal vaccine, PREVNAR 20, administered at the same time as a flu vaccine delivered positive results. Pfizer is looking into co-administering other vaccines with PREVNAR 20.

Pfizer Says Its Pneumococcal and Flu Vaccines Work Just as Well Given Together

Shares of Pfizer Inc. PFE, -1.22% gained 0.3% in premarket trading on Wednesday after the drugmaker said its combination pneumococcal and flu vaccine is safe and effective when administered at the same time. The Phase 3 study is evaluating Prevnar 20 and a flu shot in about 1,700 people 65 years old and older, testing responses from participants who got both shots at the same time and participants who got their shots a month apart.

Pfizer says administering pneumococcal and flu shots at the same time is safe and effective

GlaxoSmithKline

ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi,  presented three-year results from the TANGO study at IDWeek 2021. Phase 3 TANGO study assessed the antiviral efficacy and safety of switching to Dovato, a 2-drug regimen of dolutegravir/lamivudine in HIV-infected adults who are virologically suppressed stable on a tenofovir alafenamide fumarate (TAF)-based regimen.

ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B7471004) evaluating the safety and immunogenicity of PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in adults 65 years of age or older when administered at the same time as the seasonal influenza vaccine (SIIV, Fluad Quadrivalent [adjuvanted], 2020/2021 strains). Responses elicited by PREVNAR 20 for all 20 serotypes and by seasonal influenza vaccine when given together were

Positive Top-line Results of Pfizer's Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released

LONDON--(BUSINESS WIRE)--For media and investors only ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented three-year results from the TANGO study at IDWeek 2021, being held virtually 29 September - 3 October. Findings showed that the 2-drug regimen (2DR) Dovato (dolutegravir/lamivudine) continued to demonstrate non-inferior efficacy and a high barrier to resistance compared to co

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

Regulatory clearance of the Pfizer Inc. PFE and BioNTech SE BNTX vaccine for young children may not come until November, according to a person familiar with the matter, after the companies said they won't ask for the green light for a few weeks.

The Wall Street Journal: Pfizer's COVID vaccine for kids might not get FDA approval until November

Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.

Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies

BioNTech SE

Moderna

Novavax

Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Today

The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for pre-exposure prophylaxis (PrEP). The priority review designation sets ViiV up for a decision from the agency by January 24, 2022.

GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option

Valneva SE

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have announced more positive Phase 2 results, including the booster response, for their Lyme disease vaccine candidate VLA15. The 246-subject study is evaluating the immunogenicity and safety of VLA15 in a Month 0-2-6 vaccination schedule.

Valneva, Pfizer Lyme Disease Vaccine Candidate Drops-Off After 18 Months

Valneva, Pfizer's Phase 2 Data Suggests Booster Strategy For Lyme Disease Vaccine Candidate

Pfizer Inc (NYSE: PFE) has dosed the first participants in Phase 1 clinical trial to evaluate a single dose quadrivalent mRNA vaccine against influenza in healthy adults.  Also Read:   Moderna Puts Its First Seasonal Flu Vaccine In The Clinic

Pfizer Joins Influenza Vaccine Race, Kick Starts Early-Stage Trial

Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an emergency-use authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.

Pfizer and BioNTech seek FDA authorization for vaccination of 5- to 11-year-olds

Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an Emergency Use Authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.

Pfizer and BioNTech submit initial data to FDA from trial of COVID-19 vaccine in children aged 5 to 12

NEW YORK and MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to

Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to

LONDON--(BUSINESS WIRE)--FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV

FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV

LONDON--(BUSINESS WIRE)--VHC announces exclusive license agreement with Shionogi to develop 3rd generation HIV integrase inhibitor with potential for ultra long-acting dosing

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

Pfizer hopes to use the mRNA technology behind its Covid-19 vaccine to make a more effective flu shot.

News for Pfizer Stock (PFE)